Further characterization of Borjeson-Forssman-Lehmann syndrome in females due to de novo variants in PHF6.
Borjeson-Forssman-Lehmann syndrome
PHF6
X-chromosomal
de novo
Journal
Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
19
05
2022
received:
21
03
2022
accepted:
31
05
2022
pubmed:
7
6
2022
medline:
6
8
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
While inherited hemizygous variants in PHF6 cause X-linked recessive Borjeson-Forssman-Lehmann syndrome (BFLS) in males, de novo heterozygous variants in females are associated with an overlapping but distinct phenotype, including moderate to severe intellectual disability, characteristic facial dysmorphism, dental, finger and toe anomalies, and linear skin pigmentation. By personal communication with colleagues, we assembled 11 additional females with BFLS due to variants in PHF6. We confirm the distinct phenotype to include variable intellectual disability, recognizable facial dysmorphism and other anomalies. We observed skewed X-inactivation in blood and streaky skin pigmentation compatible with functional mosaicism. Variants occurred de novo in 10 individuals, of whom one was only mildly affected and transmitted it to her more severely affected daughter. The mutational spectrum comprises a two-exon deletion, five truncating, one splice-site and three missense variants, the latter all located in the PHD2 domain and predicted to severely destabilize the domain structure. This observation supports the hypothesis of more severe variants in females contributing to gender-specific phenotypes in addition to or in combination with effects of X-inactivation and functional mosaicism. Therefore, our findings further delineate the clinical and mutational spectrum of female BFLS and provide further insights into possible genotype-phenotype correlations between females and males.
Identifiants
pubmed: 35662002
doi: 10.1111/cge.14173
pmc: PMC9543785
doi:
Substances chimiques
PHF6 protein, human
0
Repressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
182-190Informations de copyright
© 2022 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
Références
Neurobiol Dis. 2016 Dec;96:227-235
pubmed: 27633282
Hum Mol Genet. 2021 May 12;30(7):575-594
pubmed: 33772537
Am J Med Genet A. 2009 Feb;149A(2):246-50
pubmed: 19161141
Epilepsy Behav. 2017 Apr;69:104-109
pubmed: 28237832
Neuron. 2013 Jun 19;78(6):986-93
pubmed: 23791194
Eur J Med Genet. 2014 Feb;57(2-3):85-9
pubmed: 24380767
Am J Med Genet A. 2020 Apr;182(4):689-696
pubmed: 32027463
Sci Rep. 2020 Nov 4;10(1):19030
pubmed: 33149206
Nucleic Acids Res. 2016 Apr 7;44(6):2501-13
pubmed: 26926108
Clin Genet. 2022 Sep;102(3):182-190
pubmed: 35662002
Eur J Hum Genet. 2006 Dec;14(12):1233-7
pubmed: 16912705
J Biol Chem. 2013 Feb 1;288(5):3174-83
pubmed: 23229552
Hum Mol Genet. 2013 Dec 20;22(25):5121-35
pubmed: 23906836
Acta Med Scand. 1962 Jan;171:13-21
pubmed: 13871358
Mol Syndromol. 2011 Sep;1(6):294-300
pubmed: 22190899
Clin Genet. 2004 Mar;65(3):226-32
pubmed: 14756673
Pediatr Dermatol. 2021 Jul;38(4):919-925
pubmed: 34041787
J Med Genet. 2013 Dec;50(12):838-47
pubmed: 24092917
Nat Genet. 2002 Dec;32(4):661-5
pubmed: 12415272
J Child Neurol. 2009 May;24(5):610-4
pubmed: 19264739
J Med Genet. 2003 Apr;40(4):e50
pubmed: 12676923
J Clin Res Pediatr Endocrinol. 2019 Jan 11;11(4):419-425
pubmed: 30630810
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Med Genet. 2006 Mar;43(3):238-43
pubmed: 15994862
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):290-301
pubmed: 25099957